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Psychological Support for Personality (PSP)
versus treatment as usual: study protocol
for a feasibility randomized controlled trial
of a low intensity intervention for people
with personality disorder
Mike J Crawford1,2* , Lavanya Thana1,2, Jennie Parker3, Oliver Turner4, Kwek Pei Xing1,2, Mary McMurran5,
Paul Moran6, Timothy Weaver7, Barbara Barrett8, Amy Claringbold1,2, Paul Bassett9 and Rahil Sanatinia1,2
Abstract
Background: Previous research has demonstrated the clinical effectiveness of long-term psychological treatment for
people with some types of personality disorder. However, the high intensity and cost of these interventions limit their
availability. Lower-intensity interventions are increasingly being offered to people with personality disorder, but their
clinical and cost effectiveness have not been properly tested in experimental studies. We therefore set out to develop a
low intensity intervention for people with personality disorder and to test the feasibility of conducting a randomized
controlled trial to compare the clinical effectiveness of this intervention with that of treatment as usual (TAU).
Methods: A two-arm, parallel-group, single-blind, randomized controlled trial of Psychological Support for Personality
(PSP) versus TAU for people aged over 18 years, who are using secondary care mental health services and have
personality disorder. We will exclude people with co-existing organic or psychotic mental disorders (dementia, bipolar
affective disorder, delusional disorder, schizophrenia, schizoaffective disorder, or schizotypal disorder), those with cognitive
or language difficulties that would preclude them from providing informed consent or compromise participation in study
procedures, and those who are already receiving psychological treatment for personality disorder. Participants will be
randomized via a remote system in a ratio of PSP to TAU of 1:1. Randomization will be stratified according to the referring
team and gender of the participant.
A single follow-up assessment will be conducted by masked researchers 24 weeks after randomization to assess mental
health (using the Warwick and Edinburgh Well-Being Schedule), social functioning (using the Work and Social Adjustment
Scale), health-related quality of life (EQ-5D-5 L), incidence of suicidal behavior, satisfaction with care (Client Satisfaction
Questionnaire), and resource use and costs using a modified version of the Adult Service Use Schedule. In addition to this,
each participant will be asked to complete the patient version of the Clinical Global Impression Scale.
Feasibility and acceptability will primarily be judged by study recruitment rate and engagement and retention in
treatment. The analysis will focus principally on descriptive data on the rate of recruitment, characteristics of participants,
attrition, adherence to therapy, and follow-up. We will explore the distribution of study outcomes to investigate
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assumptions of normality in order to plan the analysis and sample size of a future definitive trial.
Discussion: Most people with personality disorder do not currently receive evidence-based interventions. While a
number of high intensity psychological treatments have been shown to be effective, there is an urgent need to develop
effective low intensity approaches to help people unable to use existing treatments. PSP is a low intensity intervention for
individuals, which was developed following extensive consultation with users and providers of services for people with
personality disorder. This study aims to examine the feasibility of a randomized trial of PSP compared to TAU for people
with personality disorder.
Trial registration: ISRCTN Registry, ISRCTN14994755. Registered on 18 July 2017.
Keywords: Personality disorder, Psychological treatment, Low intensity, Brief intervention, Suicidal behavior, Randomized
trial,
Background
Personality disorders are long-term mental health condi-
tions which affect 4–7% of the general population [1].
People with personality disorder have severe problems in
their relationships with others which can lead to poor
mental health, social exclusion, and impaired quality of
life [2, 3]. No drugs are currently licensed for the treat-
ment of personality disorder; instead clinical guidelines
recommend structured psychological therapies [4, 5].
Evidence-based psychological treatments for people with
personality disorder are intensive. They typically com-
bine individual and group-based therapy delivered over a
12–18-month period [6, 7]. Most people with personality
disorder do not have access to these intensive interven-
tions and even when they are available as many as half
of those who are referred do not engage with them [8,
9]. As a result most people with personality disorder do
not receive evidence-based treatment [10]. Usual care
for people with personality disorder is often inconsistent
and many service users report negative experiences of
the care they receive [11–13].
Current guidelines for treating depression and other
common mental disorders generally recommend a
“stepped care approach” in which all patients are initially
offered a low-intensity intervention and only those who
do not respond are offered longer and more intensive
treatments [14–16]. Low intensity intervention is not a
substitute for more intensive treatments but rather an
approach which aims to increase access to appropriate
care and improve equity of access to more costly and
intensive interventions [15].
It has been argued that a stepped care approach should
also be used to treat people with personality disorder [17];
however, little research has been undertaken to develop or
test “low intensity” interventions for people with personality
disorder. As a result, very few people with personality dis-
order receive evidence-based interventions.
A systematic search for clinical trials of psychosocial in-
terventions for people with borderline personality disorder
published in 2014, found evidence from two small-scale
studies that had examined the impact of short-term advice
and support [7]. Both studies were conducted in the United
States. The first examined the impact of a single session of
psychoeducation about personality disorder and its treat-
ment [18] and the second involved six sessions of
manual-assisted cognitive therapy compared to treatment
as usual (TAU) [19]. Both studies reported short-term ben-
efits associated with these low intensity interventions. Since
the publication of this review, a further study has examined
the impact of providing people with borderline personality
disorder access to a web-based psychoeducational resource
which included information about symptoms of the condi-
tion, its etiology, and prognosis [20]. A total of 80 women
with borderline personality disorder were recruited from
the Internet. Those given access to the resource showed
greater improvements in mental health, measured using
the Zanarini Rating Scale for Borderline Personality Dis-
order, compared to those who were not. [20]. In contrast to
the promising results of these studies, no benefit was seen
among people with personality disorder who were offered a
short-term group-based problem-solving therapy for people
with personality disorder [21].
Concerns have been raised about the potential for
negative effects associated with the use of short-term
interventions for people with personality disorder [4]. A
secondary analysis of data from a brief manualized form
of cognitive behavior therapy for people with repeated
deliberate self-harm found that costs of care among
people with personality disorders were higher among
those offered the brief intervention compared to those
offered standard care [22]. Current clinical guidelines for
the treatment of people with borderline personality
disorder in the UK specifically caution against the use of
interventions lasting less than three months [4].
Despite these recommendations, mental health ser-
vices are under increasing pressure to offer low intensity
interventions to people with personality disorder. Such
interventions consist of a limited number of sessions of
psychoeducation and structured psychological support.
In keeping with recommendations of experts, particular
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attention is paid to the way interventions are delivered,
including making sure that staff delivering them are
properly supervised [23]. Such interventions aim to help
patients make links between their emotions and actions
and to improve people’s ability to care for themselves
[24, 25]. While this approach has the potential to
increase access to care and improve patient outcomes,
its clinical and cost effectiveness is unknown.
The purpose of this study is to examine the feasibility
of using a randomized trial to test the clinical and cost
effectiveness of a low intensity intervention for people
with personality disorder.
Research objectives
The main objective of the study is to find out whether it
is feasible to conduct a randomized controlled trial of
Psychological Support for Personality (PSP) versus TAU
for people in contact with mental health services who
have personality disorder. The secondary objectives of
the study are:
1. To conduct a parallel-arm, single-blind, randomized
trial of a psychologically informed low intensity
intervention for people with personality disorder;
2. To determine the uptake and delivery of both the
low intensity intervention and TAU, including the
number of sessions offered and attended;
3. To determine the rate of recruitment, distribution
of outcomes, rate of follow-up, and extent of clus-
tering between practitioners to inform the sample
size calculation for a future definitive trial;
4. To explore service user and provider beliefs about the
acceptability and design of the trial and factors that
facilitate or hinder the delivery of a low intensity
intervention for people with personality disorder.
If the study demonstrates feasibility, we will use the
results to seek funding for a phase III randomized trial.
The results of a fully powered trial would ensure that fu-
ture guidelines on the use of low intensity interventions
for people with personality disorder would be based on
high-quality evidence, rather than having to rely solely on
the expert opinion that forms the basis of current
treatment guidelines.
Methods/Design
The PSP trial is a two-arm, parallel group, single-blind, ran-
domized controlled trial with a 24-week follow-up assess-
ment. The trial includes an integrated process evaluation
which will explore service user and provider beliefs about
the impact of this intervention, mechanisms of action, and
factors that facilitate or hinder its successful delivery.
Study setting
Study participants will be recruited from secondary care
mental health services in London. Recruitment will be from
community mental health teams, home treatment teams,
and other community-based mental health services.
Eligibility criteria
The target population is adults aged 18 years or over
who have a clinical diagnosis of personality disorder and
are able and willing to provide written informed consent
to take part in the study.
The exclusion criteria are:
 A current co-existing diagnosis of an organic or
psychotic mental disorder (dementia, bipolar
affective disorder [type I and II], delusional disorder,
schizophrenia, schizoaffective disorder, or schizo-
typal disorder);
 Cognitive or language difficulties that preclude
individuals providing informed consent or
compromise participation in study procedures;
 Current receipt of psychological treatment for
personality disorder.
Interventions
Those in the active arm of the trial will be offered PSP
while those in the control arm of the trial will continue
to receive TAU.
Psychological Support for Personality
The development of the form and content of this interven-
tion was based on the recommendations of an expert panel
of service users and providers. We used a nominal group
technique to seek a consensus on the optimal form and
content of the intervention [26]. Seven clinicians and six
service users took part in the group. Service providers were
all experienced in treating people with personality disorder
and were selected to ensure a range of different professional
backgrounds and training. Service user members were
chosen because they had lived experience of using services
for people with personality disorder. Each panel member
was asked to complete a survey comprising 21 questions
on the optimal form and content of a low intensity inter-
vention for people with personality disorder. At a half-day
panel meeting, all members of the group were then given
an opportunity to discuss their preferences for the interven-
tion. Following these discussions, each panel member was
asked to re-rate their preferences in light of other panel
members’ responses to the first round of the survey and
their discussions with other panel members at the meeting.
Key findings from the second-round survey are presented
in Table 1. Qualitative comments from group members
highlighted the importance of ensuring that the interven-
tion was tailored to the specific needs of the participants.
Crawford et al. Trials  (2018) 19:547 Page 3 of 13
Table 1 Views of expert panel and their impact on the design of the active intervention
Topic Views of panel members Feature of the active intervention
Name of the
intervention
• Avoid using the term 'brief' which may give the impression
the person does not have serious problems.
• The word 'support' was preferred to the words 'intervention'
or ‘treatment’ as this recognises that people are receiving
help to better self-manage rather than something that
happens to them.
Decision to call the intervention ‘Psychological Support
for Personality’.
Target group • To try to keep this as broad as possible, because many
people with personality disorder are excluded from services
due to coexisting conditions.
To make the intervention available to people with coexisting,
non-psychotic, axis I disorders including alcohol and drug
misuse.
Number of
sessions
• Should generally offer six to 10 sessions.
• The panel recommended that no minimum or maximum
number of sessions be set.
That the therapist and service user agree the number of
sessions to be delivered following the initial assessment - but
(in general) to offer six to 10 sessions.
Contact outside
of sessions
• The panel recommended that limited telephone contact in
times of crisis could be beneficial as general crisis support
lines were often experienced as unhelpful.
• Service user members expressed the view that telephone-
based sessions were not likely to be as helpful as face-to-face
meetings, but felt that telephone-based sessions should be
offered as an alternative to face meetings if this was
the service user’s preference.
To offer limited access to telephone support at times of crisis.
Sessions to generally be offered face-to-face with the option
of telephone based sessions if service users prefer this.
Missed sessions • Service users felt that, if advance notice was given, people
should be allowed to re-schedule sessions; clinicians agreed
with this but felt that a limit needed to be placed on the
number of sessions that could be cancelled.
The therapist should reschedule session(s) if asked to do so
by the service user.
Missed sessions may be substituted, therapists should use
discretion when deciding this.
Provision of
group-based
sessions
• Concerns were expressed about the impact of isolated peer
group sessions in the context of a short term individual
intervention.
• There was a consensus that it would be appropriate to refer
people to community-based groups and other resources if these
are available.
Not to incorporate group sessions within the intervention,
but to refer service users to community-based groups outside
of the intervention if these are available.
Use of diagnostic
term ‘personality
disorder’
• Two thirds of the group were in favour of the use of the term
and a third were not, unless discussion was initiated by the
service user.
• All agreed that providing information about personality and
personality-related problems was an important part of the
intervention.
• The group recommended the use of a shared formulation to
give people a framework for trying to understand their problems
and what might help them.
The intervention includes a discussion of personality and
the origins of personality-related problems. The intervention
includes the development of a shared formulation.
Personality disorder diagnosis is discussed but only used if
the person finds this helpful.
Liaison with
primary care
• Service user members stated that the extent to which details
of the intervention were shared with their GP should depend
on the quality of their relationship with them.
• Most staff members of the group stated that information about
the intervention should be shared with the GP.
Copies of the shared formulation and final discharge plan
will be shared with the service users GP if they agree to this.
Medication • Clinicians stated that it would complicate the intervention
to include a routine review of medication.
• Service users expressed a preference for including a review
either before the intervention or at an early stage.
• All participants were concerned about the impact of side
effects of medication on peoples’ health.
To offer a review of medication to those who are concerned
about the psychotropic medication they are taking.
Involving
significant others
• Panel members agreed that this could be helpful but
emphasised the importance of ensuring that this was what
the service user wanted and making sure that service users
did not feel left out of any joint sessions.
To offer a joint meeting with a significant other if the service
user would like this.
Treatment goals • All members supported the development of person-centred
aims for the intervention.
• Service users members stated that the word 'goals' was not
ideal and may inadvertently lead people to focus on what they
had not achieved during the intervention.
• There was general agreement about the need to manage
expectations and having flexibility in reviewing progress during
the intervention.
Therapists to ensure that service users are provided with
information about the limited focus of the intervention.
Service users and therapists to agree a shared focus
(generally by the end of the second session).
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Given the short-term nature of the intervention, service
users and providers stated that it was important to set real-
istic aims for the intervention and help prepare people for
the end of the sessions.
The results of the nominal group meeting were pre-
sented to managers of the service which would deliver the
treatment and further feedback used to develop treatment
guidelines for the intervention. Key features of PSP are pre-
sented in Table 2, together with comparative information
on high intensity psychological treatments for people with
personality disorder. Further details are available on re-
quest from the corresponding author. PSP consists of 6–10
sessions of psychoeducation and psychologically informed
support for individuals. The exact number of sessions, fre-
quency, and duration offered will be based on clinical judg-
ment and patient preferences, but we anticipate that up to
ten sessions will be offered over a 3–6-month period and
that each session will last for 30–45 min.
The intervention will be delivered in accordance with
recommendations for psychosocial interventions for
people with personality disorders [25] and low intensity
interventions for people with other non-psychotic
mental disorders [27].
During the first two sessions, the therapist will assess the
patient’s mental health, personality difficulties, and existing
understanding of their problems and coping strategies in
order to formulate a treatment plan, including a crisis plan.
By the end of session two, the participant and the therapist
will agree the focus for the remaining sessions and share
this in writing with their general practitioner (GP).
The focus of the remaining sessions will depend on the
needs and preferences of the participant but may include
help with developing coping skills, support to better
understand problems in relationships, or encouragement
and advice around the person’s social and occupational
needs. During these sessions, the therapist will discuss the
nature of personality disorders, what leads people to de-
velop disturbed interpersonal functioning, and what steps
people can take to lessen the impact that aspects of their
personality can have on their quality of life. Psychological
support will draw on the two longer-term evidence-based
treatments that are most widely used in the UK: Dialect-
ical Behavior Therapy [28, 29] and Metallization-Based
Treatment [30, 31]. During sessions, therapists will seek
to “validate” the patient’s experience. Validation involves
the therapist acknowledging that a person’s feelings,
thoughts, and behaviors are valid and understandable [28].
Therapists will use a metalizing stance which involves ac-
knowledging that the mental states of others can only be
understood through curious enquiry and seeks to encour-
age people to play an active role in understanding how
mental states can affect their thoughts, feelings, and ac-
tions and those of others [30]. Attention will also be paid
to what healthcare services can and cannot do to assist
people with personality disorders and support the patient
in developing steps that they can take to look after their
own mental health. Treatment delivery mode will be
flexible, depending on patient preference, and will include
individual face-to-face and telephone contact and may be
supplemented by texts, emails, and liaison in other ser-
vices. Patients will be provided access to written and/or
web-based information and signposted to other services
as appropriate.
Following delivery of PSP, the aim will be to discharge
the study participant from secondary care mental health
services. This aim will be made explicit to potential par-
ticipants before they enrol in the study. Therapists deliv-
ering PSP will be able to refer participants to
longer-term psychological treatments or continuing care
from mental health services if appropriate to do so.
Delivering PSP
All staff delivering PSP will be registered mental health
professionals with some experience of working with
people with personality disorders. To ensure that thera-
pists are appropriately supported and that the needs of
the participant are being met, they will meet fortnightly
as part of a multidisciplinary team to discuss progress.
Staff delivering PSP will be asked to complete a short
proforma for every participant that they treat which re-
cords the number and length of face-to-face, telephone,
and email/text contacts they have had with patients and
lists the components of the intervention they delivered
during the course of the treatment. Staff will also record
any participants that have withdrawn early from the PSP
and the reason(s) for this (if known).
Treatment as usual
TAU will be delivered by staff working in community
mental health teams. This comprises assessment, care
planning, and review. It may involve pharmacotherapy
and referral to other services including access to inpatient
Table 1 Views of expert panel and their impact on the design of the active intervention (Continued)
Topic Views of panel members Feature of the active intervention
Psychological
approaches
• Service users members emphasised the importance of
psychoeducation to help people understand and cope with
stigma and self-stigma.
• Members of the panel stated that other approaches such as
mindfulness and problem-solving could be beneficial depending
on the person’s individual needs.
Psychoeducation to be the starting point for the intervention.
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care at times of crisis. As part of the local care pathway
for people with personality disorder, staff are asked to dis-
cuss the care pathway (including discharge from second-
ary care) from the outset. Staff delivering TAU will be able
to refer participants to longer-term psychological treat-
ments but any patient who is already receiving psycho-
logical treatment for personality disorders at the time of
the baseline assessment will not be eligible to take part in
the study.
All study participants allocated to receive TAU will
complete all the study assessments. Clinical teams will
not be asked to complete a proforma on any usual treat-
ment that is being delivered; instead this information
will be captured in the Modified Adult Service User
Schedule at baseline and six months.
Assessments
The timing and sequence of all assessments are summa-
rized in Fig. 1.
Baseline: eligibility and covariates
At baseline, we will collect demographic details and as-
sess eligibility using the Standardized Assessment of Se-
verity of Personality Disorder (SASPD) [32]. A score ≥ 8
on the SASPD provides a reliable assessment of the like-
lihood of personality disorder according to ICD-11 cri-
teria [32]. Those who score < 8 on the SASPD will not
be eligible to take part in the study. Those who are ineli-
gible will be thanked for their time and informed of the
reason(s) for this. We will also ask participants to
complete the International Personality Disorder Examin-
ation (IPDE) Screening Questionnaire, a 77-item
self-complete questionnaire, which provides a reliable in-
dication of specific personality disorders using DSM-IV
criteria [33]. We will use data from the IPDE to describe
the range of personality problems experienced by people
who take part in the study.
Baseline: study outcomes
Study participants will be asked to complete the follow-
ing outcome measures: (1) The Work and Social Adjust-
ment Scale (a short validated assessment of social
functioning) [34]; (2) The Warwick and Edinburgh
Well-Being Schedule – a seven-item questionnaire
which provides a reliable assessment of mental wellbeing
[35, 36]; (3) Suicidal thoughts-National Household Sur-
vey of Psychiatric Morbidity [37]; (4) the five-item
EQ-5D-5 L, a reliable self-completed assessment of
health-related quality of life [38] which has been shown
to be sensitive to change among people with personality
disorders [39]; (5) satisfaction with care will be examined
using the four-item Client Satisfaction Questionnaire
[40]; (6) resource use and costs will be assessed using a
modified version of the Adult Service Use Schedule [41];
and (7) participants will be asked to rate any change in
their mental health during the previous six months using
the Clinical Global Impression Scale (CGI), a
seven-point Likert scale from very much improved to
very much worse [42]. Finally, participants will be asked
to state how confident they are in their ability to “get
yourself through difficult times and situations” on a
five-point Likert scale (ranging from totally confident to
totally unconfident). The psychometric properties of this
item have not been tested. It was included in the study
following feedback with stakeholders with lived experi-
ence of personality disorders.
Follow-up assessments
All study participants will complete a six-month
follow-up assessment. At the six-month follow-up, the
researcher will ensure that all the study outcomes that
were assessed at baseline are reassessed, i.e. the Work
and Social Adjustment Scale, the Warwick and Edin-
burgh Well-Being Schedules, suicidal thoughts and be-
havior using items from the National Household Survey
of Psychiatric Morbidity, the EQ-5D-5 L, the Client Sat-
isfaction Questionnaire, the Adult Service Use Schedule,
patient-rated Clinical Global Impression and the
five-point Likert scale on how confident they are in their
ability to manage crises.
In addition to this, we will seek additional consent
from study participants to take part in a qualitative
interview. Following completion of the six-month
follow-up interview, up to 20 participants will be invited
to take part in a separate interview with a researcher
with lived experience of using mental health services.
During this interview, participants will be asked about
their experience of taking part in the study and any steps
they think we could take to improve the design of a fu-
ture definitive trial. The interview will be
semi-structured and guided by a topic list which will be
applied flexibly. The sample for this qualitative compo-
nent of the study will be purposively selected to ensure
that men and women of different ages and ethnicities
are selected from those in both the active and control
arm of the trial. Participants from the active arm of the
trial will also be selected to ensure that both those who
engage and drop out of PSP are included.
Sample size
In keeping with recommendations for feasibility studies,
we have not based plans for sample size on a power cal-
culation [43]. Instead we judged that a sample of 60 par-
ticipants will generate sufficient data to assess the rate of
recruitment and follow-up in a single center and esti-
mate levels of uptake and retention in therapy among
approximately 30 people in the active arm of the trial.
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Assignment of interventions
After consenting to participation and completing screening
assessments, people who are found to be eligible will be
randomly allocated to PSP or TAU by a clinical trial man-
ager at the Centre for Psychiatry, Imperial College London.
A randomization list will be generated using the independ-
ent web-based service “sealed envelope” (https://www.seale-
denvelope.com/simple-randomiser/v1/lists). Equal numbers
of participants will be randomized to the two arms of the
trial and stratification will occur by gender and study cen-
ter. Throughout the study, the randomization list will be
encrypted and held with the Trial Coordinating Office in
order to keep the study researchers blind against treatment
allocation. At the end of the study the randomization list
will be unencrypted and placed in the Trial Master File.
Equal numbers of participants will be randomized to each
arm of the trial. Randomization will be stratified according
to the referring team and gender of the participant.
Blinding
The randomization service will generate a unique trial
identification number for that participant, which will be
used on Case Report Forms. Research assistants will be
blind to allocation status of participants, but the partici-
pants and those providing clinical care will not. Re-
searchers will be asked to keep a contemporaneous record
of any instances in which treatment allocation is disclosed
to them. When a researcher is unblinded, we will arrange
for a second researcher who is blinded to complete the
six-month follow-up assessment.
Study logistics
Recruitment
Potential participants will initially be approached about
the study by any healthcare professional who is involved
in their care. If staff have a patient under their care who
they believe meets the eligibility criteria for the study,
they will introduce the patient to the study at an appro-
priate time by briefly describing it to them. The patient
must provide verbal agreement to discuss their eligibility
and possible enrolment into the trial with a member of
the research team before any further study process can
take place. If a patient gives verbal agreement, a re-
searcher will phone them to explain the study in greater
detail. The researcher will then post or email a copy of
the patient information sheet. Potential participants will
be given no less than 24 h from receiving the informa-
tion sheet to consider the information and the oppor-
tunity to question the researcher or other independent
parties about their participation in the trial. Researchers
will then arrange to meet potential participants to obtain
written informed consent. A copy of the signed In-
formed Consent form(s) will be given to the patient. The
original signed form(s) will be retained at the trial site.
We will aim to recruit the study sample of an
eight-month period.
Fig. 1 Study assessment schedule
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Screening, baseline, and follow-up interviews
If consent is given and documented, a Screening Assess-
ment Case Report Form will be completed with the partici-
pant. If the participant fulfils the eligibility criteria, they will
then complete the Baseline Assessment and be randomized
(see Fig. 2). Following randomization, the participant’s GP
and referring clinician will be informed of their enrolment
into the trial.
Study participants will be contacted at three months
by a study researcher to confirm contact details and as a
reminder about the six-month assessment. A follow-up
interview will then be scheduled for six months after
randomization. All participants will be offered a £20
honorarium following completion of the six-month
follow-up interview.
Adverse events
All adverse events (AEs) will be recorded from the time
a participant gives consent until 30 days after participa-
tion. In keeping with EU guidance on the collection and
verification of AE reporting in clinical trials, serious
adverse events (SAE; i.e. those that result in death, are
life-threatening, require hospitalization or prolongation
of existing inpatients’ hospitalization, or result in persist-
ent or significant disability or incapacity) and non-SAEs
will be recorded on event forms, detailing as much of
the event as possible to be reviewed and signed by Prin-
cipal Investigator [44]. The Principal Investigator will as-
sess: (1) the seriousness of the event; (2) the likelihood
of causality to the event; and (3) the severity of the
event. The Researcher will ask participants during any
contact or scheduled visit about AEs.
The study may be subject to inspection and audit by
Central and North West London NHS Foundation Trust
under their remit as sponsor and other regulatory bodies
to ensure adherence to GCP and the NHS Research
Governance Framework for Health and Social Care.
Data management and analysis
Data will be entered into a password-protected Micro-
soft Excel spreadsheet/database held on a secure server.
Study data will be archived securely and then safely
Fig. 2 Study flow chart
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destroyed after 15 years. Analysis and reporting of the
trial will be in accordance with CONSORT guidelines.
Data analysis will focus principally on descriptive data
on recruitment rates, characteristics of participants, at-
trition from the trial, non-adherence to therapy, and
follow-up. The effect of treatment on outcomes will be
estimated on an intention-to-treat basis using differences
in scores on study outcomes and confidence intervals. We
will explore the distribution of the outcomes to investigate
assumptions of normality in order to plan the analysis and
sample size for the definitive trial. We will also analyze the
cost of the intervention using data from the proformas
completed by those delivering PSP. We will also estimate
costs of TAU that participants receive using data from the
Adult Service Use Schedule. These data will allow us to
identify the main cost components which would need to
be captured in a subsequent phase, full-scale trial.
Contemporaneous notes will be made during each
interview and uploaded to NVivo analytical software be-
fore thematic analysis [45]. To generate an initial coding
framework, an independent thematic analysis will be
conducted on a sample of transcripts and a session held
to discuss and refine the thematic structure. This initial
coding frame may be further refined as the analysis pro-
gresses in response to emergent themes. Supported by
NVivo, the coding framework will be applied to the data
(indexing) with the aim of allocating all data to a theme.
Where new codes are identified, previously coded tran-
scripts will be re-checked to ensure that extracts of data
are coded consistently throughout. Full copies of notes
will be retained to ensure context is maintained. The
aim of the analysis will be to describe the range of expe-
riences and responses to the intervention, highlighting
any patterns and divergences in respondent accounts
which support the key research questions relating to
feasibility, acceptability, and optimization of both the
intervention and trial design.
Progression criteria
Our criteria for determining the success of the feasibility
study are: recruitment of at least 48 participants (80% of
the target study sample of 60 participants); uptake of the
low intensity intervention by at least 60% of participants
in the active arm of the trial; and completion of follow-up
interviews at six months by 75% of study participants. To
determine the feasibility of calculating a cost analysis of
health economics, we will record completion rates for the
cost data and analyze them to determine what the main
cost-drivers are likely to be in a full clinical trial.
Ethics
Approval for the research has been given by the South
Central Research Ethics Committee (Ref: 16/SW/0255)
and from the Research and Development departments of
the participating NHS Trust. We will ensure that the
trial is conducted in full conformity with the current re-
vision of the Declaration of Helsinki (last amended 13/
09/2017. Version 4.0) and with the Medicines for Hu-
man Use (Clinical Trials) Regulation 2004 transposed
into law from the EU Clinical Trials Directive 2001/20/
EC, the EU Good Clinical Practice Directive 2005, and
all current and future acts and requirements pertaining
to its conduct.
Each study participant will be assigned a unique trial
identification number at the start of the assessment
process. This number will be written on all clinical assess-
ment forms/datasheets and databases used to record data
on study participants. A hard copy of a record sheet link-
ing patient identity, contact details, and trial identification
number for all participants will be kept at each site. It will
be placed in the Investigator Site File, in a locked filing
cabinet, separate from the paper Case Report Forms and
other documents relating to a participant, which will be
anonymized. Recorded data will be entered onto an elec-
tronic data management system that will use the trial
identification number rather than the participant’s name
or other information that could identify them.
Discussion
This trial aims to generate data to test the feasibility of
using a randomized trial to examine the effects of a low in-
tensity intervention for people with personality disorders.
Current guidance from the National Institute for Health
and Care Excellence caution against the use of brief inter-
ventions for people with borderline personality disorder
[4]. Despite this guidance, mental health services are under
increasing pressure to try to ensure that more people with
personality disorders receive evidence-based interventions
and treatments. PSP is a new approach aimed at helping
people with personality disorders, which is delivered to
individuals rather than to groups of people, and is based
on principles derived from longer-term interventions for
people with personality disorders and recommendations of
an expert panel of service users and providers.
PSP is a person-centered intervention which allows thera-
pists and patients to develop an agreed plan for providing
short-term psychoeducation and support that focuses on
what matters most to the patient. Rather than attempting
to treat the person’s personality, PSP aims to provide people
with information about the nature of personality-related
problems and psychological approaches derived from
longer-term psychological treatments that may help people
improve their mental health.
This trial has a number of strengths and limitations. It
is designed to be pragmatic with broad inclusion criteria,
limited exclusion criteria, and relatively short outcome
assessment.
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By enabling people with substance misuse problems,
including substance dependence, to take part in the
study we will be testing an intervention for an important
group of people with personality disorders who are often
excluded from existing interventions for people with this
condition [46]. Unlike most trials of interventions for
people with personality disorders, we will not make
entry into the study dependent on a potential participant
meeting validated criteria for the condition. Instead poten-
tial participants will need to meet criteria for “probable”
personality disorders using the SASPD. We have decided
not to include a more formal examination of personality
disorders, because validated semi-structured instruments
designed to make these assessments are lengthy (often
taking > 1 h to complete). Furthermore, in a previous trial
of problem-solving therapy for people with personality
disorders in a secondary care setting, we found that nearly
all those referred to the trial (650/682, 95.3%) met the cri-
teria for personality disorders; those that did not still had
significant personality pathology [47].
The trial combines the collection of both qualitative and
quantitative data in order to make a comprehensive as-
sessment of the acceptability and feasibility of the study
design and in an effort to generate data that could help in-
form the design of a larger future explanatory trial.
We will be assessing the feasibility and acceptability of a
range of outcomes. These are based on recommendations
of both users and providers of services for people with
personality disorders [48]. By including the patient version
of the CGI Scale in the follow-up interview we will be able
to examine whether the two treatment conditions are as-
sociated with negative as well as positive changes for par-
ticipants. This information, together with the qualitative
data we will be collecting, will enable us to examine con-
cerns about possible negative effects of short-term inter-
ventions for people with personality disorders [4, 47].
Limitations of the trial include the absence of de-
tailed information about the “type” of personality dis-
orders which patients experience and the relatively
short follow-up period. Our use of the SASPD will
ensure that we will have reliable information about
the severity of the personality disorders of study par-
ticipants but will not enable us to describe the pro-
portion of people who meet criteria for borderline,
antisocial, and other specific personality disorders
[32]. While this will limit our ability to compare the
results of the trial with results of previous trials of
borderline personality disorder, we have purposefully
adopted an approach to the diagnosis of personality
disorders that will form the basis of revised World
Health Organization criteria which are primarily
based on severity of interpersonal functioning and
sense of self rather than type of personality-related
problems [49].
We decided to restrict the length of follow-up in the
study to six months because our primary aim was to es-
tablish the rate of recruitment in the trial as well as the ac-
ceptability and uptake of the intervention we are testing.
However, personality disorders are long-term conditions
and a future larger-scale explanatory trial would benefit
from having a longer-term follow-up of 12–18 months.
This trial faces a number of challenges which will
need to be overcome if we are to recruit to target. In
addition to pressures of workload and other factors
that may deter clinicians from referring people to
clinical trials, staff may be concerned about the im-
pact of their patient being randomized to “treatment
as usual,” which many consider unsatisfactory. Clinical
staff may prefer the option of referring patients for
assessment for psychological treatment from a psych-
ologist or psychotherapist. However, such services
typically have long waiting lists and referral criteria
which exclude some of the patients we aim to recruit
to this study (such as those judged at risk of severe
self-harm and those with coexisting substance mis-
use). Potential participants may also be unhappy
about the prospect of being randomly allocated to the
two arms of the trial and may have a preference ei-
ther for continuing to receive care from their existing
team or for receiving the new intervention that we
are testing. For this reason, we have designed patient
information sheets to reflect the similarities as well as
the differences between the two treatment conditions
in the trial. For instance, both treatment conditions
aim to work with people in the short to medium
term with a view to discharging the patient from
secondary care mental health services. Participants in
both arms of the trial will also have access to other
secondary care services including crisis helplines,
review of medication, and referral to longer-term psy-
chological therapies if these are indicated. We will be
examining the views of study participants on this and
other aspects of the trial design as part of the process
evaluation we are conducting in parallel to the
randomized trial.
Conclusions
This trial has the potential to increase the quality of
care that people with personality disorders currently re-
ceive by paving the way for an explanatory trial of a low
intensity treatment that would enable more people with
personality disorders to access and potentially benefit
from effective support aimed at helping them achieve
better mental health and social functioning.
Trial status
Recruitment is ongoing (50 participants recruited as of
end of May 2018).
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